MANKIND2023-01-012023-03-31 MANKIND2023-01-012023-03-31 MANKIND2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member MANKIND2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member MANKIND2023-03-31 MANKIND2023-01-012023-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member MANKIND2023-01-012023-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member MANKIND2023-01-012023-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member MANKIND2023-01-012023-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member MANKIND2023-01-012023-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member MANKIND2023-01-012023-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member MANKIND2023-01-012023-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member MANKIND2023-01-012023-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543904 MANKIND NOTLISTED Mankind Pharma Limited Equity 2022-04-01 2023-03-31 2023-05-30 2023-05-22 INR Lakhs Yearly 17:05:00 18:45:00 2023-05-30 2023-05-30 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceuticals 2023-01-01 2023-03-31 Audited Consolidated 20526670000.00 475112000.00 21001782000.00 4620953000.00 1982046000.00 133789000.00 4958840000.00 51554000.00 845211000.00 4664243000.00 17256636000.00 3745146000.00 0.00 3745146000.00 891158000.00 -55287000.00 835871000.00 0.00 2909275000.00 0.00 0.00 0.00 27707000.00 2936982000.00 38992000.00 2975974000.00 2854386000.00 82596000.00 2892661000.00 83313000.00 400588000.00 1 7.13 7.13 0.00 0.00 7.13 7.13 Explanatory notes to the Statement of Audited Consolidated Financial Results for the quarter and year ended March 31, 2023 1 These audited consolidated financial results of the Holding Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standard) rules, 2015 . The said financial results represent the results of Mankind Pharma Limited ( Holding Company ) and its subsidiaries (the Holding Company and its subsidiaries together referred to as the Group ), its associates and joint ventures for the quarter and year ended March 31, 2023. 2 These audited consolidated financial results have been reviewed by the Audit Committee at its meeting held on May 30, 2023 and have been approved by Board of Directors at its meeting held on May 30, 2023. These results have been audited by the joint statutory auditors of the Holding Company. 3 Subsequent to the Balance sheet date, the Holding Company has completed its Initial Public Offer (IPO) of 4,00,58,844 equity shares of face value INR 1 each at and issue price of INR 1,080 per share. The issue comprised of 100% offer for sale aggregating to INR 4,32,635.52 lacs. Pursuant to IPO, the equity shares of the Holding Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on May 9, 2023. 4 The Group is primarily engaged in manufacturing and trading of pharmaceuticals and consumer healthcare products. The Group has only one reportable segment 'Pharmaceuticals' and accordingly disclosures as per Ind AS 108 Operating Segments are not applicable. 5 The Holding Company in the month of May 2021, filed a scheme of merger with National Company Law Tribunal (NCLT) for merging two of its wholly owned subsidiaries Lifestar Pharma Private Limited and Magnet Labs Private Limited with the Holding Company. NCLT approval for the said merger was received by the Holding Company vide order dated March 02, 2023. Pursuant to this, the Holding Company has accounted the said scheme in accordance with Appendix C of Ind AS 103 Business Combinations and accordingly comparative period presented have been restated to give effect of the scheme. 6 During the current quarter, 10,46,512 options have been granted under the Mankind Employees Stock Option Plan 2022 to the eligible employees of the Group. No options have been vested and exercised during the quarter. Single segment 2022-04-01 2023-03-31 Audited Consolidated 87494330000.00 1285668000.00 88779998000.00 18136635000.00 8092376000.00 2907409000.00 19184715000.00 444690000.00 3259195000.00 20166829000.00 72191849000.00 16588149000.00 0.00 16588149000.00 3275558000.00 340075000.00 3615633000.00 0.00 12972516000.00 0.00 0.00 0.00 124242000.00 13096758000.00 -18875000.00 13077883000.00 12818591000.00 278167000.00 12799316000.00 278567000.00 400588000.00 1 73951640000.00 32.00 32.00 0.00 0.00 32.00 32.00 Other expenses 4664243000.00 Other expenses 20166829000.00 1880701000.00 25237990000.00 4931920000.00 53696000.00 200225000.00 17014633000.00 569536000.00 2709485000.00 0.00 1101814000.00 3811299000.00 297769000.00 733550000.00 52850618000.00 14984582000.00 10754741000.00 5764214000.00 3048207000.00 1483779000.00 16326000.00 559797000.00 21627064000.00 1025153000.00 6633918000.00 44270717000.00 33156000.00 97154491000.00 400588000.00 73951640000.00 74352228000.00 76232929000.00 283245000.00 283245000.00 978888000.00 773121000.00 254946000.00 2290200000.00 1420464000.00 10081769000.00 2364918000.00 13867151000.00 1225352000.00 3076304000.00 462555000.00 18631362000.00 20921562000.00 97154491000.00 7 Subsequent to the year end in the month of May 2023, the Income Tax Department (‘the department’) conducted a search under section 132 of the Income Tax Act, 1961 at Holding Company’s registered office, corporate office, few of its manufacturing locations and other premises and few of its group entities and residence of few of its employees/key managerial personnel. During the search proceedings, the Holding Company has provided necessary information and responses to the department. Also, the department has taken certain documents, data backups and other information for further investigation. The business and operations of the Holding Company continued without any disruptions and no demands have been raised on the Holding Company as of date. Based on the foregoing and having regard to the matters of inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these consolidated financial results in this regard. 8 a) The figures for the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and March 31, 2022 and audited year to date figures up to end of nine months of the current financial year and previous financial year respectively. b) The figures for the quarter ended December 31, 2022 are the balancing figures between the audited figures in respect of the year to date figures up to December 31, 2022 and the unaudited year-to-date figures up to September 30, 2022 as approved by the board of directors of the Holding Company. 9 Other expenses includes impairment of non current assets being investment in associate amounting to INR 500 lacs provided in year ended March 31, 2023 and having consequential impacts in quarter/period ended December 31, 2022 and March 31, 2022 (also refer note 8 above). 10 During the previous year, the Holding Company had acquired pharmaceutical formulation brands including their related trademarks and copyrights and other Intellectual Property Rights from Panacea Biotec Pharma Limited and Panacea Biotec Limited relating to their operations in India and Nepal. Accordingly, prior period numbers are not comparable to current period. 444690000.00 2617799000.00 -2053148000.00 0.00 2955615000.00 0.00 0.00 -1292975000.00 0.00 -650193000.00 0.00 -603993000.00 0.00 3259195000.00 0.00 532074000.00 0.00 162110000.00 0.00 39584000.00 24000.00 127640000.00 0.00 0.00 0.00 0.00 80141000.00 -587400000.00 0.00 4775835000.00 21363984000.00 0.00 0.00 0.00 3230967000.00 0.00 18133017000.00 0.00 38273000.00 0.00 0.00 -62442000.00 0.00 0.00 0.00 60479000.00 7890205000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 430485000.00 0.00 0.00 0.00 0.00 4094000.00 0.00 0.00 0.00 24000.00 127640000.00 0.00 -2303931000.00 0.00 -10541287000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10985798000.00 17938231000.00 30030000.00 0.00 0.00 414818000.00 0.00 0.00 -7397281000.00 194449000.00 23154000.00 217603000.00 2830604000.00 3048207000.00 Re-measurement losses on defined benefit plans 56868000.00 Share of other comprehensive income/ (loss) of associates and joint ventures -109000.00 Change in the fair value of equity investments at FVTOCI 2696000.00 Re-measurement losses on defined benefit plans -78049000.00 Share of other comprehensive income/ (loss) of associates and joint ventures 685000.00 Change in the fair value of equity investments at FVTOCI 3631000.00 59455000.00 -73733000.00 23585000.00 -25678000.00 Exchange differences in translating the financial statements of foreignnoperations 3122000.00 Exchange differences in translating the financial statements of foreignnoperations 29180000.00 3122000.00 29180000.00 0.00 0.00